[go: up one dir, main page]

ES2123721T3 - Formulaciones de rapamicina para inyecciones por via intravenosa. - Google Patents

Formulaciones de rapamicina para inyecciones por via intravenosa.

Info

Publication number
ES2123721T3
ES2123721T3 ES94307115T ES94307115T ES2123721T3 ES 2123721 T3 ES2123721 T3 ES 2123721T3 ES 94307115 T ES94307115 T ES 94307115T ES 94307115 T ES94307115 T ES 94307115T ES 2123721 T3 ES2123721 T3 ES 2123721T3
Authority
ES
Spain
Prior art keywords
rapamicine
solution
formulations
intravenous injections
percent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94307115T
Other languages
English (en)
Inventor
Robert Paul Waranis
Thomas Leonard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Application granted granted Critical
Publication of ES2123721T3 publication Critical patent/ES2123721T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

ES DESCRITO EN ESTO UNA SOLUCION RAPAMICINA INYECTABLE, ACUOSA QUE COMPRENDE EL 40 AL 75 POR CIENTO DE VOLUMEN DE UNA SOLUCION CONCENTRADA DE RAPAMICINA EN GLICOL PROPILENO, A CONCENTRACIONES CLASIFICADAS DE 0.25 MG/ML A 8 MG/ML, EN COMBINACION CON UNA SOLUCION DILUYENTE QUE COMPRENDE AGUA, EN DONDE EL DILUYENTE COMPRENDE 60 A 25 POR CIENTO DE VOLUMEN DE LA SOLUCION COMBINADA Y LA CONCENTRACION DE RAPAMICINA EN LA MAGNITUD DE SOLUCION COMBINADA DESDE 0.1 MG/ML A 4 MG/ML.
ES94307115T 1993-09-30 1994-09-29 Formulaciones de rapamicina para inyecciones por via intravenosa. Expired - Lifetime ES2123721T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12952693A 1993-09-30 1993-09-30

Publications (1)

Publication Number Publication Date
ES2123721T3 true ES2123721T3 (es) 1999-01-16

Family

ID=22440429

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94307115T Expired - Lifetime ES2123721T3 (es) 1993-09-30 1994-09-29 Formulaciones de rapamicina para inyecciones por via intravenosa.

Country Status (11)

Country Link
US (1) US5616588A (es)
EP (1) EP0650729B1 (es)
KR (1) KR100376192B1 (es)
AT (1) ATE172120T1 (es)
AU (1) AU689488B2 (es)
DE (1) DE69413923T2 (es)
DK (1) DK0650729T3 (es)
ES (1) ES2123721T3 (es)
FI (1) FI944537L (es)
HU (1) HU219236B (es)
SG (1) SG47715A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616588A (en) * 1993-09-30 1997-04-01 American Home Products Corporation Rapamycin formulation for IV injection
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
US5989591A (en) * 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US5985325A (en) * 1997-06-13 1999-11-16 American Home Products Corporation Rapamycin formulations for oral administration
US6682758B1 (en) 1998-12-22 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Water-insoluble drug delivery system
US6670355B2 (en) 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
DE60136200D1 (de) 2000-09-19 2008-11-27 Wyeth Corp Wasserlösliche rapamycin-ester
US6399625B1 (en) 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
AU2003210787B2 (en) 2002-02-01 2009-04-23 Medinol Ltd. Phosphorus-containing compounds & uses thereof
CA2493878C (en) 2002-07-30 2013-07-23 Wyeth Parenteral formulations containing a rapamycin hydroxyester
JP2006511475A (ja) * 2002-09-18 2006-04-06 トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア 脈絡膜新生血管症の抑制方法
WO2005027906A1 (en) * 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
KR100562800B1 (ko) * 2004-04-26 2006-03-23 이영기 소형 전기세탁기용 탈수통 클러치장치
JP5214966B2 (ja) * 2004-07-30 2013-06-19 ノバルティス アーゲー ２−アミノ−１，３−プロパンジオール化合物およびその類似体の製剤
GB2438544A (en) * 2005-02-09 2007-11-28 Cooper Internat Corp Liquid formulations for treatment of diseases or conditions
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
CA2635797C (en) * 2006-02-09 2015-03-31 Macusight, Inc. Stable formulations, and methods of their preparation and use
CN101443004B (zh) 2006-03-23 2013-03-06 参天制药株式会社 用于与血管通透性有关的疾病或病症的制剂
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
KR101267813B1 (ko) 2009-12-30 2013-06-04 주식회사 삼양바이오팜 향상된 수용해도를 갖는 라파마이신 함유 고분자나노입자 주사제형 조성물 및 그 제조방법, 및 방사선 요법과 병용하기 위한 항암 조성물
KR102305844B1 (ko) * 2014-01-29 2021-09-28 삼성전자주식회사 세탁기 및 그 제어방법
EP3755303A1 (en) 2018-02-23 2020-12-30 Biotronik AG Parenteral formulation materials and methods for 40-o-cyclic hydrocarbon esters and related structures

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) * 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US4885171A (en) * 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
AU543727B2 (en) * 1980-06-02 1985-05-02 Ayerst Mckenna & Harrison Inc. Injectable composition of rapamycin
US4894366A (en) 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
JPH0734373B2 (ja) * 1989-11-15 1995-04-12 ヒロセ電機株式会社 コネクタ
KR0177158B1 (ko) * 1990-03-01 1999-03-20 후지사와 도모기찌로 면역억제 활성을 갖는 트리사이클릭 화합물 함유 용액 제제
GB9103430D0 (en) * 1991-02-19 1991-04-03 Smithkline Beecham Plc Novel compound
US5080899A (en) * 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
NZ251628A (en) * 1992-03-30 1996-07-26 American Home Prod Aqueous insectable rapamycin solution; product containing concentrate and diluent solutions
US5616588A (en) * 1993-09-30 1997-04-01 American Home Products Corporation Rapamycin formulation for IV injection

Also Published As

Publication number Publication date
ATE172120T1 (de) 1998-10-15
HK1012230A1 (en) 1999-07-30
DE69413923D1 (de) 1998-11-19
FI944537A7 (fi) 1995-03-31
FI944537A0 (fi) 1994-09-29
KR950007855A (ko) 1995-04-15
US5616588A (en) 1997-04-01
KR100376192B1 (ko) 2005-08-18
DK0650729T3 (da) 1999-06-23
HUT71101A (en) 1995-11-28
EP0650729B1 (en) 1998-10-14
HU9402808D0 (en) 1995-01-30
FI944537L (fi) 1995-03-31
AU7435394A (en) 1995-04-13
AU689488B2 (en) 1998-04-02
HU219236B (en) 2001-03-28
DE69413923T2 (de) 1999-05-12
EP0650729A1 (en) 1995-05-03
SG47715A1 (en) 1998-04-17

Similar Documents

Publication Publication Date Title
ES2123721T3 (es) Formulaciones de rapamicina para inyecciones por via intravenosa.
UY25055A1 (es) Formulaciones farmacéuticas que contienen voriconazol
ES2123101T3 (es) Formulacion de rapamicina para inyeccion intravenosa.
CO5190689A1 (es) Sales de tramadol formadas por tramadol y un edulcorante y formas farmaceuticas que contienen dichas sales
ES2039898T3 (es) Acondicionamiento para una composicion liquida lista para su uso realizada a partir de una composicion liquida concentrada y procedimiento de realizacion.
ES2148224T3 (es) Formulacion de rapamicina para inyecciones intravenosas.
CO5271759A1 (es) Formulacion en solucion que contiene una mezcla de disolventes
BR0311877A (pt) Preparações ácidas de insulina com estabilidade aperfeiçoada
AR032409A1 (es) Metodos para la administracion de analogos de epotilona para el tratamiento de cancer
AR011846A1 (es) Una composicion farmaceutica, y el procedimiento para prepararla
ES2085652T3 (es) Soluciones estabilizadas de peracido.
BR0014869A (pt) Composição e método para estabilização da mesma
SV2002000969A (es) Composicion parenteral reconstituible
ATE273033T1 (de) Stabilisierte ophthalmische wasserstoffperoxidlösung
ES2192256T3 (es) Soluciones farmaceuticas inyectables que contienen paracetamol y combinaciones de paracetamol con otras sustancias activas.
MX9301749A (es) Liquidos estructurados que contienen amido e imido peroxiacidos.
ES2171444T3 (es) Una solucion intravenosa que disminuye las perdidas de proteinas y de agua corporales.
KR900007424A (ko) 세포보호성 약제로서의 n-아세틸글루코사민의 사용방법 및 그 조성물
GT199200009A (es) Composicion farmaceutica y su utilizacion en el tratamiento contra el cancer e infecciones viricas.
ES2067864T3 (es) Tratamiento de la hipertension ocular con una combinacion sinergica para administracion ocular.
ES2082345T3 (es) Composicion del tipo de barra con cloruro de sodio y alcohol estearilico.
KR920014474A (ko) 담석 붕괴용 제제
KR960701638A (ko) 안정화된 주사제 및 주사제의 안정화법
ECSP034422A (es) Inhibidores de la trombina que contiene un grupo de aminoisoquinolina
AR002981A1 (es) Un envase que aloja una composicion farmaceutica que comprende una solucion acuosa de clorhidrato de procaterol, y una composicion farmaceutica quecomprende una solucion acuosa de clorhidrato de procaterol

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 650729

Country of ref document: ES